FMC CORPORATION
boothcheck covers FMC CORPORATION (FMC) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 26, 2026.
• Revenue fell to 3,467.4 million dollars in 2025 from 4,246.1 million, with Asia alone dropping to 142.3 million from 848.4 million as FMC took roughly 422 million dollars of one-time revenue charges preparing its India business for sale [Source: FY2025 Form 10-K]. • Rynaxypyr, the insect-control active ingredient that produced about 0.8 billion dollars of revenue in 2025, is now past patent protection, and managing that transition is one of management's stated priorities for the year [Source:
Is FMC overvalued? See what's priced in →
424 institutional managers reported holding FMC in 13F filings for the quarter ended 2026-03-31. Together they hold about 91% of the company; the top 10 hold 52%. 86 opened new positions that quarter. Held by BlackRock, Vanguard Group, AQR Capital, among others. On the short side, 19.5M shares were sold short as of the 2026-06-15 count, about 16% of shares outstanding (6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
FMC has cut its share count 3% over the past five years, spending $877.20M on repurchases. It pays a dividend, and has paid one every year in our records (19 and counting); the current rate is $1.82 a share annually. Cash returned over the past three years: $1.38B in dividends and $85.30M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at FMC over the trailing three years: 2023: 3 buys totaling $428k; 2024: 1 buy totaling $127k; 2025: 5 buys totaling $2.60M; 2026: 1 buy totaling $250k. 23 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
FMC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -3.2% | -31.4% |
| 2023-11-08 | -5.4% | +13.5% |
| 2024-02-28 | -13.0% | +12.6% |
| 2024-05-08 | +7.9% | -15.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
FMC's latest 8-K filings: 2026-07-29 (items 2.02, 9.01); 2026-07-01 (items 1.01, 3.02, 7.01, 9.01); 2026-06-23 (items 1.01, 2.03, 9.01); 2026-06-23 (items 1.01, 9.01); 2026-06-05 (items 1.01, 2.03, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 26, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.